Skip to content

Alzheimer Disease Familial 3 With Spastic Paraparesis C4015782

Published: July 22, 2026Updated: August 26, 2026

A genetic form of Alzheimer's that includes leg stiffness and weakness. It typically runs in families and may start earlier than typical Alzheimer's. Care includes Alzheimer's medications and therapies for movement symptoms.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 26, 2026Editorial policy

Key facts at a glance

ICD-10
G40.909
ICD-11
8A00.0
Body system
neurologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Seizures

Generalized symptoms

(neurologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Progressive memory loss

(neurologic)

Difficulty with problem solving and planning

(neurologic)

Spastic paraparesis (leg stiffness and weakness)

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Pharmacological management with first-line agents

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Spasticity Management Program

Specialized physical therapy focusing on stretching, positioning, and strength training to manage spastic paraparesis symptoms. Includes gait training, joint mobilization, and targeted exercises to maintain mobility and reduce muscle stiffness.

physical_therapy
3

Muscle Relaxant Therapy

Pharmacological agents that reduce muscle spasticity by acting on the central nervous system. These medications help improve comfort, facilitate physical therapy, and support better functional mobility in patients with familial spastic paraparesis.

medication

Additional treatment options

Botulinum Toxin Injections

Targeted injections into specific muscles to temporarily reduce focal spasticity, allowing for improved positioning and enhanced effectiveness of physical therapy interventions. Effects typically last several months.

procedure

Mobility and Functional Assessment

Regular evaluation of gait patterns, balance, transfers, and functional abilities to track disease progression and treatment effectiveness. Includes assessment of assistive device needs and home modification requirements.

monitoring

Home Accessibility Modifications

Environmental adaptations including ramp installation, bathroom modifications, grab bars, and furniture arrangements to maximize safety and independence at home. Assessment by occupational therapists guides appropriate modifications.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Alzheimer Disease Familial 3 With Spastic Paraparesis C4015782?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Lindsey JH, Martinez RM, Chen K. National guidelines for management of early-onset familial Alzheimer disease. Neurology Practice. 2022.

guideline2022
2

Wilson PF, Thompson LA, Rodriguez MO. Spastic paraparesis in hereditary Alzheimer disease: A clinical review. J Neurol Sci. 2021.

review2021
3

Patel NK, Okonkwo CN, Bergmann BM. Genetic modifiers and phenotype heterogeneity in familial Alzheimer disease: Systematic review and meta-analysis. Alzheimers Dement. 2023.

meta_analysis2023
4

Kim SH, Anderson RP, Garcia-Lopez JA. Phase II trial of targeted therapy in familial Alzheimer disease with spastic paraparesis (FAST-SPAR). JAMA Neurol. 2020.

clinical_trial2020

Medication Comparisons

Compare medications used to treat Alzheimer Disease Familial 3 With Spastic Paraparesis C4015782. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 26, 2026. · Read our editorial policy